Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, May 23, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that the following\n posters will be presented on AEZS-108, the Company's lead oncology\n compound, at the upcoming American Society of Clinical Oncology\n (\"ASCO\") annual meeting, which will be held May 31 to June 4, 2013, in\n Chicago.\n\n\n\n\n\n\n\n\nAbstract # 5062: \n\n\n\"A Phase 1 Dose Escalating Trial of AEZS-108 in Taxane- and\n Castration-Resistant Prostate Cancer\", J. Pinski, A.V. Schally, D. Tsao-Wei, T.B. Dorff, S. Groshen,\n S. Xiong, D. Quinn, Y. Tai, J. Engel, S.V. Liu.\n\n\n\n\nPresenter: \n\n\nJacek Pinski, MD, PhD, USC Norris Comprehensive Cancer Center,\n California\n\n\n\n\nDate & Time: \n\n\nMonday, June 3, 2013, from 8:00 am to 11:45 am (central)\n\n\n\n\nVenue: \n\n\nS Hall 2, McCormick Place, Chicago\n\n\n\n\n\n\n\n\n\n\n\n\n\nAbstract # TPS 11124: \n\n\n\"A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory\n Triple-Negative (ER/PR/HER2-Negative) LHRH-R Positive Metastatic Breast\n Cancer\", S. Buchholz, J.B. Engel, A.V. Schally, S. Seitz, O. Ortmann, G. Emons,\n R.L. Mahtani, S. Glück, C. Vogel, A.J. Montero.\n\n\n\n\nPresenter: \n\n\nStefan Buchholz, MD, Medical Center University of Regensburg, Germany\n\n\n\n\nDate & Time: \n\n\nMonday, June 3, 2013, from 1:15 pm to 5:00 pm (central)\n\n\n\n\nVenue: \n\n\nS Hall 2, McCormick Place, Chicago\n\n\n\n\n\n\n\n\n\n\nA third abstract (# e15596) on AEZS-108, \"A Case Report of a Long-Term Response in a Patient with Urothelial\n Cancer (UC) Treated with AEZS-108\", G. L. Fernandez, A. V. Schally, T. Koru-Sengul, M. Jorda, J. R.\n Merchan, A. M. Flores, N. L. Block, M. Manoharan, J. Engel, is\n currently available online on ASCO's website, but will not be presented during a poster session. The abstract\n reports on the first patient with LHRH-R positive UC treated with\n AEZS-108 in an ongoing Phase 1 clinical trial.\n\n\nAbout AEZS-108 (doxorubicin peptide conjugate)\n\n\nAEZS-108 represents a new targeting concept in oncology using a hybrid\n molecule composed of a synthetic peptide carrier and a well-known\n chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug\n in advanced clinical development that directs the chemo...

More updates from Cosciens Biopharma Inc.